Use of ACE inhibitors is associated with elevated levels of IGFBP-3 among hypertensive older adults: results from the IlSIRENTE study

• Published in: European journal of clinical pharmacology Vol. 63; no. 4; pp. 389 - 395
• Main Authors: Onder, Graziano, Liperoti, Rosa, Russo, Andrea, Capoluongo, Ettore, Minucci, Angelo, Lulli, Paola, Cesari, Matteo, Maggio, Marcello, Bernabei, Roberto, Landi, Francesco
• Format: Journal Article
• Language: English
• Published: Heidelberg Springer 01.04.2007; Berlin Springer Nature B.V
• Subjects: Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors - pharmacology; Angiotensin-Converting Enzyme Inhibitors - therapeutic use; Arterial hypertension. Arterial hypotension; Biochemistry; Biological and medical sciences; Blood and lymphatic vessels; Cardiology. Vascular system; Clinical Trials as Topic; Dose-Response Relationship, Drug; Enzymes; Female; Geriatrics; Humans; Hypertension; Hypertension - blood; Hypertension - drug therapy; Inhibitor drugs; Insulin-Like Growth Factor Binding Protein 3 - blood; Insulin-Like Growth Factor I - metabolism; Male; Medical sciences; Pharmacology; Pharmacology. Drug treatments; Human; Hypertension; Insulin-like growth factor binding protein-3; Insulin like growth factor binding protein 1; Ace inhibitors; Cardiovascular disease; Hypertension·IGF-1· IGFBP-3·Older adults; Insulin like growth factor 1; Elderly; ACE inhibitor
• ISSN: 0031-6970; 1432-1041
• DOI: 10.1007/s00228-007-0262-z

Several studies in vitro or in rodent models have suggested a potential relationship between angiotensin-converting enzyme (ACE) inhibition and the insulin-like growth factor 1 (IGF-1) axis. However, this relationship has only rarely been investigated in humans. The aim of the present cross-sectional study was to assess the association of ACE inhibitors with free IGF-1 and IGFBP-3 in the blood of older hypertensive adults. Data are from the baseline evaluation of the IlSIRENTE study, which enrolled 364 subjects aged 80 or older. For the present study we selected a subpopulation of 264 hypertensive participants without congestive heart failure. Free IGF-1 and IGFBP-3 in the blood were measured by a radioimmunoassay method. Analyses of covariance were performed to evaluate the differences in free IGF-1 and IGFBP-3 levels according to the use of ACE inhibitors. The mean age of participants was 85.7 years (SD: 4.9), 170 (64%) were women and 123 (47%) were using an ACE inhibitor. Following adjustment for potential confounders, the concentration of free IGF-1 was slightly, but not significantly higher among ACE inhibitor users than among non-users (0.74 vs. 0.65 ng/mL; p=0.20). In contrast, ACE inhibitor users had a significantly higher IGFBP-3 serum levels than non-users (4821 vs. 4330 ng/mL; p=0.005). In addition, the concentration of IGFBP-3 was significantly higher among ACE inhibitors users than among non-users of antihypertensive drugs (p=0.02) and users of other antihypertensive drugs (p=0.01). Among hypertensive older adults, ACE inhibitors use is associated with higher IGFBP-3 levels.